Gain Therapeutics Inc. (GANX)
Gain Therapeutics Statistics
Share Statistics
Gain Therapeutics has 26.53M shares outstanding. The number of shares has increased by 63.54% in one year.
| Shares Outstanding | 26.53M |
| Shares Change (YoY) | 63.54% |
| Shares Change (QoQ) | 3.88% |
| Owned by Institutions (%) | 6.31% |
| Shares Floating | 25.22M |
| Failed to Deliver (FTD) Shares | 1.5K |
| FTD / Avg. Volume | 0.63% |
Short Selling Information
The latest short interest is 658.34K, so 2.48% of the outstanding shares have been sold short.
| Short Interest | 658.34K |
| Short % of Shares Out | 2.48% |
| Short % of Float | 2.61% |
| Short Ratio (days to cover) | 1.65 |
Valuation Ratios
The PE ratio is -1.91 and the forward PE ratio is -2.65. Gain Therapeutics's PEG ratio is -0.12.
| PE Ratio | -1.91 |
| Forward PE | -2.65 |
| PS Ratio | 771.06 |
| Forward PS | 0.6 |
| PB Ratio | 3.38 |
| P/FCF Ratio | -2.25 |
| PEG Ratio | -0.12 |
Enterprise Valuation
Gain Therapeutics Inc. has an Enterprise Value (EV) of 31.78M.
| EV / Earnings | -1.43 |
| EV / Sales | 575.93 |
| EV / EBITDA | -1.43 |
| EV / EBIT | -1.43 |
| EV / FCF | -1.68 |
Financial Position
The company has a current ratio of 3.59, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.59 |
| Quick Ratio | 3.59 |
| Debt / Equity | 0.08 |
| Total Debt / Capitalization | 7.55 |
| Cash Flow / Debt | -18.36 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.77% and return on capital (ROIC) is -164.14%.
| Return on Equity (ROE) | -1.77% |
| Return on Assets (ROA) | -1.2% |
| Return on Capital (ROIC) | -164.14% |
| Revenue Per Employee | 1.9K |
| Profits Per Employee | -767.85K |
| Employee Count | 29 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 79.28K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -54.7% in the last 52 weeks. The beta is 0.15, so Gain Therapeutics's price volatility has been higher than the market average.
| Beta | 0.15 |
| 52-Week Price Change | -54.7% |
| 50-Day Moving Average | 2.16 |
| 200-Day Moving Average | 1.83 |
| Relative Strength Index (RSI) | 46.71 |
| Average Volume (20 Days) | 239.71K |
Income Statement
In the last 12 months, Gain Therapeutics had revenue of 55.18K and earned -22.27M in profits. Earnings per share was -1.71.
| Revenue | 55.18K |
| Gross Profit | -25.2K |
| Operating Income | -22.25M |
| Net Income | -22.27M |
| EBITDA | -22.17M |
| EBIT | -22.25M |
| Earnings Per Share (EPS) | -1.71 |
Balance Sheet
The company has 11.79M in cash and 1.03M in debt, giving a net cash position of 10.77M.
| Cash & Cash Equivalents | 11.79M |
| Total Debt | 1.03M |
| Net Cash | 10.77M |
| Retained Earnings | -60.78M |
| Total Assets | 14.37M |
| Working Capital | 9.15M |
Cash Flow
In the last 12 months, operating cash flow was -18.87M and capital expenditures -15.36K, giving a free cash flow of -18.88M.
| Operating Cash Flow | -18.87M |
| Capital Expenditures | -15.36K |
| Free Cash Flow | -18.88M |
| FCF Per Share | -1.45 |
Margins
Gross margin is -45.67%, with operating and profit margins of -40.33K% and -40.35K%.
| Gross Margin | -45.67% |
| Operating Margin | -40.33K% |
| Pretax Margin | -40.21K% |
| Profit Margin | -40.35K% |
| EBITDA Margin | -40.18K% |
| EBIT Margin | -40.33K% |
| FCF Margin | -34.22K% |
Dividends & Yields
GANX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -80.66% |
| FCF Yield | -33.5% |
Analyst Forecast
The average price target for GANX is $7.5, which is 253.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.5 |
| Price Target Difference | 253.8% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -6.02 |
| Piotroski F-Score | 3 |